QNRX · Quoin Pharmaceuticals, Ltd.

Quoin Pharmaceuticals' Q1 2026 results showed a net loss widening to $5 million from $3.8 million year-over-year, driven by ongoing clinical investments in its rare disease pipeline, particularly QRX003 for Netherton Syndrome. Despite the loss expansion, the company's cash position of approximately $14 million in cash, equivalents, and marketable securities as of March 31 provides visibility into 2027, supporting key milestones without near-term dilution risk. CEO Dr. Michael Myers highlighted transformative regulatory momentum: U.S. FDA Fast Track Designation on March 11 enables frequent interactions and potential accelerated paths; a constructive Type C meeting on March 25 suggested a single Phase 3 trial could support marketing approval, with flexibility on design avoiding traditional controls like vehicle or placebo, streamlining costs and timelines. Internationally, Saudi SFDA Breakthrough application (Jan 20) and Japan MHLW Orphan Drug/Fast Track confirmation (Jan 27) position QRX003 for expedited access via existing MENA partnership and planned Japanese subsidiary. Phase 3 recruitment remains on track for year-end completion, with topline data H2 2026 and NDA potential in 2027 as first Netherton treatment. QRX009 topical rapamycin advances with investigator studies in Pachyonychia Congenita, Gorlin Syndrome, Tuberous Sclerosis Complex starting later 2026 and IND Q3. Extended Rare Pediatric PRV eligibility through 2029 adds monetization option post-approval. Investors should monitor upcoming 10-Q for full details, but regulatory de-risking enhances QRX003's value proposition in orphan dermatology.